Description
Indication & Scope
Camrelizumab Injection (AiRuiKa®) is a humanized anti-PD-1 monoclonal antibody. It binds to PD-1 on T cells, blocks PD-1/PD-L1 immune checkpoint pathway, restores T cell anti-tumor immune function, activates systemic anti-tumor immunity to kill cancer cells.
- Mechanism
Block PD-1 checkpoint pathway, restore T cell anti-tumor immune activity - Drug class
PD-1 Immune Checkpoint Inhibitor / Monoclonal Antibody Anti-tumor Immunotherapy - Clinical use
Multiple malignant tumors including classical Hodgkin’s lymphoma, liver cancer, lung cancer, esophageal cancer, nasopharyngeal carcinoma, cervical cancer
| Generic Name | Camrelizumab Injection |
| Brand Name | AiRuiKa® |
| Ingredient | Camrelizumab |
| Dosage Form | Injection |
| Package | 200mg/vial |
| Conditions Treated | Relapsed/refractory classical Hodgkin’s lymphoma after at least two lines of systemic chemotherapy;Advanced hepatocellular carcinoma;EGFR/ALK-negative advanced non-squamous non-small cell lung cancer (first-line combined chemotherapy);Advanced esophageal squamous cell carcinoma;Recurrent/metastatic nasopharyngeal carcinoma;Cervical cancer and other advanced malignancies |
| Taboos | Hypersensitivity to camrelizumab or any excipients |
| Place of origin | Jiangsu,China |
| Priscription Type | Prescription Drug, Class B Medicare |
| Storage Conditions | Store at 2℃-8℃, protected from light, do not freeze |
| Manufacturer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | S20190027 |
| Date of Revision | November 5, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: 200mg, intravenous infusion, once every 2 weeks; infused over 30–60 minutes, do not rapid bolus
Time: Intravenous slow infusion over 30–60 minutes, do not give as rapid IV push
Interaction: Risk of severe immune-related adverse events when combined with immunosuppressants/corticosteroids; monitor closely; do not mix directly with other infusions
Side effects: Immune-related adverse reactions (thyroid dysfunction, pneumonitis, hepatitis, colitis, reactive capillary hemangiomatosis), fever, fatigue, rash, elevated liver enzymes, infusion reactions
Important Notice
This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What should we do if fever and chills occur during infusion?
Slow down the infusion rate and inform the doctor immediately.
What kind of tumors is camrelizumab used for in the digestive tract?
Advanced esophageal squamous cell carcinoma.
Does camrelizumab kill cancer cells directly?
No, it activates the body’s own immune system to kill cancer cells.
Can hemodialysis patients use it freely?
No, use under close medical monitoring.
AiRuiKa® | Camrelizumab for Injection | Advanced Hepatocellular Carcinoma | DengYueRX
INN: Camrelizumab
Indications: Advanced Hepatocellular Carcinoma
Dosage Form: Injection
Strength: 200mg/Vial
Original price was: $551.60.$468.86Current price is: $468.86.
